## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.3% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($95.02)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel**
- Source: Business Wire | 20251202T010953 | Bullish | Relevance: 98%
-  Incyte (Nasdaq:INCY) has announced the appointment of Richard Hoffman as Executive Vice President and General Counsel, effective December 1, 2025. Mr. Hoffman brings over 20 years of experience in corporate governance and business development, having previously served as a Partner at Goodwin's Life Sciences group. He will be a key member of the Executive Leadership Team, overseeing the Company's legal and compliance functions.

**2. Incyte Corp. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251201T170600 | Neutral | Relevance: 98%
-  Incyte Corp. (INCY) stock fell by 2.32% to $102.04 on Monday, marking its second consecutive day of losses. This underperformance occurred during a general market downturn, with the S&P 500 Index and Dow Jones Industrial Average also experiencing declines.

**3. Incyte Form 4: Principal Accounting Officer reports stock sales**
- Source: Stock Titan | 20251130T050906 | Neutral | Relevance: 98%
-  Incyte Corporation's Principal Accounting Officer reported selling 769 shares of common stock across two transactions in late November 2025, with sales at $102 and $103 per share. Following these transactions, the officer directly holds 23,573 shares. The filing also indicates that the officer holds 15,166 unvested restricted stock units.

**4. Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel**
- Source: Yahoo Finance | 20251201T050000 | Bullish | Relevance: 98%
- Incyte has appointed Richard Hoffman as its new Executive Vice President and General Counsel, effective December 1, 2025. Hoffman brings over 20 years of experience in corporate governance and business development, having previously served as a partner at Goodwin’s Life Sciences group. He will be a key member of the Executive Leadership Team, overseeing legal and compliance functions and supporting Incyte's growth and innovation initiatives.

**5. Incyte’s Tafasitamab Extension Study: A Boost for Hematologic Malignancies Treatment**
- Source: MSN | 20251130T173624 | Bullish | Relevance: 98%
- Incyte (INCY) announced significant positive results from the final analysis of its long-term extension study of tafasitamab, an antibody-drug conjugate. The study, conducted in partnership with MorphoSys, demonstrated sustained and clinically meaningful responses for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Tafasitamab continues to show a well-tolerated safety profile consistent with previous findings, reinforcing its importance as a treatment option.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 13 ($23.25M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.2% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $23M sold (13 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.9B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 13.2 |
| Current P/E | 14.8 |
| YoY Growth | 12.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from -0.1% to -4.3% (-4.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.3pp (needs >3.0% for momentum thesis). Underperforming sector by 4.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.33x) but short-term weakness (below SMA20). MACD histogram bearish (-0.91), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.32% (CS: 10) | Weak |
| RSI_14 | 52.0 | Neutral |
| MACD Histogram | -0.91 | Bearish |
| vs SMA20 | 0.971x | Below |
| vs SMA50 | 1.075x | Above |
| vs SMA200 | 1.333x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.44
- **Stop Loss:** $95.02 (6.3% risk)
- **Target:** $107.86 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 155
- **Position Value:** $15,723.20
- **Portfolio %:** 15.72%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*